Pharmaceutical market access strategist reviewing gross-to-net analytics

GTN Shield

Gross-to-Net Optimization for Pharmaceutical Market Access

GTN Shield is a transaction-level financial modeling platform designed by , PharmD, RPh, LSSBB, of Health Bridge Consultants.

Open GTN Modeler

The Platform

Model GTN impact across Hub, GPO, PBM, Distribution, and Cross-Channel arrangements over a 0–36 month planning horizon with FMV-based analysis, BFSF compliance scoring, and scenario comparison.

Explore solutions

By the Numbers

0–36

Month dynamic GTN planning horizon

5

Channels: Hub, GPO, PBM, Distribution & Cross-Channel

17+

Years of market access & GTN leadership

Modeler
Osama M. Elhelw, HealthBridge: Building the bridge between patients and therapies

What We Solve

Solutions & Platform Features

01

FMV-Based Modeling

Pre-loaded Fair Market Value ranges for real-world Hub, GPO, PBM, and distribution transaction types with override capability.

02

BFSF & Compliance

Four-prong BFSF eligibility analysis, safe harbor assessments, and AMP/Best Price risk indicators for every transaction.

03

Scenario Comparison

Save and compare up to two GTN scenarios side-by-side with bar chart diffs and detailed breakdown metrics.

04

340B & Specialty Pharmacy

Built-in 340B TPA reconciliation logic and specialty pharmacy transaction modeling for complete GTN visibility.

05

PDF Reporting

Export a professional, branded PDF report of your GTN model including all selected transactions and aggregate metrics.

06

AI-Powered GTN Advisor

Ask the GTN Advisor AI about any transaction, compliance question, or modeling scenario and get expert-level guidance instantly.

Our Platform

About GTN Shield, Built by Osama M. Elhelw

GTN Shield is developed and maintained by Osama M. Elhelw, PharmD, RPh, LSSBB, Managing Director of Health Bridge Consultants, a specialized advisory practice based in Short Hills, NJ, focused on pharmaceutical patient access strategy, market access design, and GTN modeling.

GTN Shield is a financial modeling platform built for pharmaceutical manufacturers, market access teams, compliance officers, and finance leaders who need precise, transaction-level Gross-to-Net (GTN) analysis. The platform models GTN impact across a dynamic 0–36 month planning horizon, delivering visibility into the true net revenue impact of Hub services, GPO contracts, PBM arrangements, and distribution programs.

Gross-to-Net deductions are among the hardest financial variables to forecast in pharmaceutical commercialization. GTN Shield addresses this by providing pre-loaded Fair Market Value (FMV) ranges for real-world transaction types, BFSF four-prong eligibility analysis, safe harbor assessments, AMP/Best Price impact indicators, and transaction-level LRP projections, all in one modeling workspace.

Users select from a curated library of transaction types spanning Hub, GPO, PBM, Distribution, and Cross-Channel categories, input their monthly volume and WAC assumptions, and receive immediate low/median/high cost projections with cumulative GTN % impact over the selected time horizon. The built-in compliance layer surfaces legal and regulatory risk flags so teams can model with confidence before committing to contractual arrangements.

GTN Shield is designed for pharmaceutical manufacturers of all sizes, from emerging specialty biotechs launching their first product to established manufacturers managing complex, multi-channel GTN portfolios across hundreds of SKUs and service arrangements.

GTN Shield is developed and maintained by Osama M. Elhelw, PharmD, RPh, LSSBB, Managing Director of Health Bridge Consultants, a specialized advisory practice based in Short Hills, NJ, focused on pharmaceutical patient access strategy, market access design, GTN modeling, and 340B program management.

Gross-to-net financial waterfall analytics on a monitor

Advisory Services

Market Access, GTN & Hub Optimization Consulting

Gross-to-Net (GTN) Optimization

Gross-to-net (GTN) optimization is the process of modeling and reducing the gap between a drug's list price (wholesale acquisition cost, WAC) and the net revenue the manufacturer keeps after rebates, chargebacks, fees and discounts. It turns GTN from an after-the-fact accounting number into a forecastable, contract-level plan.

  • Transaction-level GTN forecasting over a 0–36 month horizon
  • Rebate, chargeback and fee waterfall modeling
  • Launch Reference Pricing (LRP) support
42 CFR § 447.504 (AMP)

Bona Fide Service Fees (BFSF) & Fair Market Value

A bona fide service fee (BFSF) is a fee a manufacturer pays for a real, itemized service at fair market value that it would otherwise perform itself, and that is not passed on to a customer. Fees that meet all four tests are excluded from AMP and Best Price.

  • Four-prong BFSF eligibility review
  • Single-point FMV benchmarks with documented cost builds
  • Safe harbor and Best Price impact flags
42 CFR § 447.502 (BFSF)

Specialty Pharmacy, Hub & FRM Harmonization

Hub-to-FRM harmonization is the alignment of a hub vendor's patient-access workflows (benefits verification, prior authorization, case management) with field reimbursement managers so cases hand off without gaps or duplicated work. It shortens time-to-therapy and lowers cost per patient.

  • Hub services design and vendor SOW structure
  • Specialty pharmacy network and data-feed design
  • FRM deployment and non-promotional guardrails
42 CFR § 1001.952(d) (safe harbor)

340B Program Compliance

340B compliance means making sure discounted 340B purchases are used only for eligible patients of covered entities and are not also claimed for Medicaid rebates (duplicate discounts). For manufacturers it covers ceiling-price accuracy, contract pharmacy policy and claims-data reconciliation.

  • Duplicate-discount identification
  • 340B claims-data and TPA reconciliation
  • Contract pharmacy policy impact modeling
42 U.S.C. § 256b (340B)

DTC / DTP Patient Support Models

Direct-to-patient (DTP) and direct-to-consumer (DTC) models let a manufacturer sell or ship a therapy to patients through a contracted pharmacy, often on a cash-pay basis, outside traditional PBM channels. They need careful pricing, fulfillment-fee and Anti-Kickback design.

  • Cash-pay pricing and channel strategy
  • Fulfillment and telehealth vendor fee design
  • Federal program carve-out and compliance review
42 U.S.C. § 1320a-7b (AKS)

Advisory Services at a Glance

Advisory services, governing rule and deliverable
Gross-to-Net (GTN) OptimizationKey rule: 42 CFR § 447.504 (AMP)Deliverable: GTN waterfall model and contract scenarios
Bona Fide Service Fees (BFSF) & Fair Market ValueKey rule: 42 CFR § 447.502 (BFSF)Deliverable: BFSF/FMV assessment by transaction
Specialty Pharmacy, Hub & FRM HarmonizationKey rule: 42 CFR § 1001.952(d) (safe harbor)Deliverable: Hub architecture and patient-journey playbook
340B Program ComplianceKey rule: 42 U.S.C. § 256b (340B)Deliverable: 340B exposure model and controls
DTC / DTP Patient Support ModelsKey rule: 42 U.S.C. § 1320a-7b (AKS)Deliverable: DTC/DTP operating model and fee schedule

Questions & Answers

Frequently Asked Questions

About the Platform

What is GTN Shield?

GTN Shield is a transaction-level Gross-to-Net financial modeling platform for pharmaceutical manufacturers. It models GTN impact across Hub, GPO, PBM, Distribution, and Cross-Channel arrangements over a 0–36 month planning window using FMV-based cost ranges and compliance analysis.

Who built GTN Shield?

GTN Shield was built by Osama M. Elhelw, PharmD, RPh, LSSBB, Managing Director of Health Bridge Consultants, a pharmaceutical market access and GTN advisory practice based in Short Hills, NJ.

Modeling & Planning

How does GTN Shield calculate transaction-level LRP?

GTN Shield applies Fair Market Value (FMV) low and high ranges to each selected transaction type, multiplied by monthly volume and the planning horizon in months, producing cumulative low/median/high cost projections that can be used directly in Launch Reference Pricing models.

What does month 0–36 dynamic planning mean?

GTN Shield projects cumulative GTN costs from the first month of a program through up to 36 months, with a visual cumulative cost chart that distinguishes BFSF-eligible, conditional, and non-eligible spend to support long-range budget planning and contract negotiation.

Compliance & FMV

How does GTN Shield support FMV and BFSF review?

Each transaction type includes a pre-loaded FMV methodology, documented value range, and BFSF four-prong eligibility analysis. Users can override FMV values with their own inputs and toggle BFSF-eligible items in or out of the model to understand their net financial exposure.

How does GTN Shield handle safe harbor compliance?

GTN Shield surfaces safe harbor status, AMP/Best Price considerations, and compliance risk notes for each transaction type, enabling legal and compliance teams to review arrangements in the same workflow as the financial model.

Get in Touch

Contact Osama M. Elhelw

Have questions about GTN Shield, need help with your analysis, or want to discuss custom GTN modeling, market access strategy, or 340B program support with Osama M. Elhelw, PharmD, RPh, LSSBB? Reach out directly.

Osama M. Elhelw, PharmD, RPh, LSSBB

Managing Director, Health Bridge Consultants (Short Hills, NJ)

osama@healthbridgedtc.com

Health Bridge Consultants

healthbridgedtp.com

Ready to model your GTN impact?

Join pharmaceutical market access professionals using GTN Shield to optimize Gross-to-Net financial outcomes.

Get Started